News

News

Analysis on COVID-19 Clinical Trials Reveals Disorganization and Wasted Resources

An analysis cosponsored by STAT and AppliedXL, a Newlab Venture Studio company, found that clinical trials for treatments and preventative strategies for COVID-19 were...

New FDA Platform Criticized for Lack of Demographic Information

The new FDA platform, Project Patient Voice, is a public database of patient-reported outcomes for clinical trials of cancer treatments intended to give patients...

Congress Seeks Formal Investigation Into Foreign Investment in US Pharmaceutical Industry

On June 30, Senators Elizabeth Warren (D-MA) and Marco Rubio (R-FL) introduced the U.S. Pharmaceutical Supply Chain Review Act, calling for a formal investigation...

FDA Approves New HIV Treatment for Patients With Restricted Treatment Options

The FDA has approved fostemsavir for adult patients with HIV who have tried multiple medications and whose HIV infection cannot be successfully treated with...

White House Further Suspends Work Visas, Affecting Science and Tech

The White House has announced the restriction of several categories of work visas for non-American citizens, in response to high unemployment levels following the...

FDA Approves Oral Selinexor for Relapsed/Refractory DLBCL

The FDA has granted accelerated approval to selinexor for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL...

Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing Recurrent Cancer-Associated VTE

In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to...

Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma

The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was...

FDA Grants Orphan Drug Designation to MT-401 for AML

The FDA has granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute myeloid leukemia (AML). MT-401, from Marker Therapeutics,...
ASH Directions

ASH Selects Next Congressional Fellow, and more

ASH Selects Next Congressional Fellow Jerome Seid, MD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow....
Advertisement

Current Issue

July 2020 Volume 6 Issue 8

This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.